Rochester, New York 12/31/2009 4:10:00 AM
News / Business

Orsus (NYSE Amex: ORS) Sees Lower 2009 Revenues 29% Less Than 2008

At its Annual Meeting of Shareholders held recently, Orsus Xelent Technologies, Inc. (NYSE Amex: ORS), a China-based designer and manufacturer of award-winning mobile phones for the Asian market, said it anticipates full year 2009 revenues of approximately $77 million, which would be approximately 29% lower than revenues in 2008.

 

Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.

 

Though the Company remains optimistic about improving sales in 2010 which will include higher margin 3G products;  Mr. Guoji Liu, CEO of the Company, stated, "In our fourth quarter, most of our sales were of lower end products with lower margins, as we continued to battle difficult industry and economic conditions. Under the circumstances, while not happy with our results, we were pleased we could face up to the challenges posed and continued to be profitable with our revamped sales strategy."  Mr. Liu told shareholders that in 2010 the Company is optimistic about a more "stabilized" environment which he believes will permit the Company to achieve steadily improving sales throughout the year. He also told shareholders that the Company believes "approximately 20% of its sales in 2010 will be of its own higher margin 3G products." A complete transcript of Mr. Liu's remarks at the Annual Meeting is available in the Form 8-K

 

Follow us on Twitter: http://www.twitter.com/pennystockspro

 

Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

 

About Us

 

Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

 

Please click here to read the full disclaimer.